linjc16/ctgov huggingface dataset:
Tobacco Pilot Study for Low Income Smokers

Study Overview
=================
Brief Summary
-----------------
Pilot study to test feasibility of delivering a motivational smoking cessation intervention to low income smokers via a computer tablet.

Detailed Description
-----------------
Twenty Salvation Army clients will be recruited to pilot test a motivational smoking cessation counseling intervention that is delivered via a tablet computer. Study participants will be given brief instructions on how to use the tablet. They will then complete a brief survey on the tablet. This will be followed by the researcher using the tablet to provide the motivational intervention. Finally, study participants will be interviewed to establish this perceptions of the intervention.

Official Title
-----------------
Tobacco Pilot Study for Low Income Smokers

Conditions
-----------------
Tobacco Use Disorder

Intervention / Treatment
-----------------
* Behavioral: Tablet-guided tobacco intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: current smoker (≥ 10 cigarettes/week for the past six months who are not currently trying to quit) age ≥ 18 years English speaking/writing Exclusion Criteria: not receiving services for the Salvation Army

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: tablet-guided<br>Study participants will be administered a brief tobacco intervention by a Salvation Army staff person who is guided by a tablet computer | Behavioral: Tablet-guided tobacco intervention<br>* This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ease of use of tablet-guided tobacco intervention assessed by interview and summarized across study participants | At the end of the intervention, each study participant will be interviewed regarding how easy the tablet computer was to use. This qualitative information will by summarized across all study participants. | Immediately after exposure to intervention |
Covid-19 Epidemic on Acute Stroke Management

Study Overview
=================
Brief Summary
-----------------
The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).

Official Title
-----------------
Impact of th Covid-19 Epidemic on Acute Stroke Management

Conditions
-----------------
Stroke, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient Stroke Patients Patient who agreed to participate in this study Exclusion Criteria: - Refusal to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of the effect of pandemic covid-19 on the management of stroke patients |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
STROKE , Acute, Covid-19, SARS-COV-2, Mechanical thrombectomy, Thrombolysis
Phase 2 Study - Erdosteine in Patients With CB/COPD

Study Overview
=================
Brief Summary
-----------------
This clinical study is designed to explore dose ranging and identify methods to demonstrate the efficacy of Erdosteine in patients with stable Chronic Bronchitis associated with Chronic Obstructive Pulmonary Disease.

Official Title
-----------------
A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Dose_Ranging Study of Erdosteine for the Treatment of Stable Chronic Bronchitis Associated With Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Drug: Erdosteine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with a clinical diagnosis of stable CB associated with COPD will be entered into this study. CB is diagnosed clinically in patients who have a documented smoking history and who have a daily productive cough for at least 3 months per year over at least 2 consecutive years in the absence of other causes of chronic cough. COPD is defined by the presence of airflow obstruction from spirometry Exclusion Criteria: asthma, bronchiectasis, or cystic fibrosis; active history of lung cancer, respiratory failure, or a need for long-term oxygen therapy;

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Erdosteine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
Do Superfast Broadband and Tailored Interventions Improve Use of E-health and Reduce Health Related Travel?

Study Overview
=================
Brief Summary
-----------------
Lack of internet infrastructure, personal skills, and service provision have been identified as potential barriers to e-health but as yet there is no good evidence of the impact of interventions to improve them. This study aims to assess impact on e-health uptake of three interventions (i) superfast broadband, (ii) a tailored leaflet to help participants improve personal internet skills and support, (iii) GP interventions to improve health service provision of e-health. In a cluster randomised factorial controlled trial, 1388 households from 78 postcodes were randomly selected from the 20088 Cornish postcodes and allocated to the 8 (2X2X2) arms of the study. Comparison of 'e-health readiness' and 'miles travelled' from baseline to 18 month follow-up between the 8 arms of the study, will be used to assess the effects of interventions, singly and in combination.

Official Title
-----------------
Do Superfast Broadband and Tailored Interventions Improve Use of E-health and Reduce Health Related Travel?

Conditions
-----------------
eHealth

Intervention / Treatment
-----------------
* Behavioral: Tailored Leaflet
* Behavioral: GP visit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 16+ and member of randomly selected household within Cornwall Exclusion Criteria: Non Cornish households

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Non Superfast<br> | |
| Other: Non Superfast GP intervention<br> | Behavioral: GP visit<br> <br> |
| Other: Non Superfast Tailored Leaflet<br> | Behavioral: Tailored Leaflet<br> <br> |
| Other: Non Superfast GP + Tailored Leaflet<br> | Behavioral: Tailored Leaflet<br> <br> Behavioral: GP visit<br> <br> |
| No Intervention: Superfast<br> | |
| Other: Non Superfast GP<br> | Behavioral: GP visit<br> <br> |
| Other: Superfast Tailored Leaflet<br> | Behavioral: Tailored Leaflet<br> <br> |
| Other: Superfast GP + Tailored Leaflet<br> | Behavioral: Tailored Leaflet<br> <br> Behavioral: GP visit<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PERQ Ehealth score |  | 18 month |
The Performance of Pulse Oximeters in Pediatric Patients With Low Oxygen Saturation Levels

Study Overview
=================
Brief Summary
-----------------
Evaluate pulse oximeters with children after cardiopulmonary by-pass under low Oxygen conditions.

Official Title
-----------------
The Performance of Nellcor OxiMax N-560 and Masimo SET Radical Pulse Oximeters in Pediatric Patients With Low Oxygen Saturation Levels

Conditions
-----------------
Cardiopulmonary Bypass

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Include pediatric patients with a baseline Sa02 < 90% and no contraindications to using an adhesive sensor.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric, Oxygen Saturation, Cardiopulmonary bypass
Liver Cauterization Increases the Postoperative Pain After Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
Laparoscopic cholecystectomy is a common accepted surgical operation with lower morbidity all over the world for gallstone. Although it has low morbidity, postoperative pain is challenging situation like every other operation.

Detailed Description
-----------------
Postoperative pain after laparoscopic cholecystectomy has a three component: parietal, visceral and referring (shoulder) pain. Although intensities of them can be various, all of them affects the total pain together. Unintentional liver cauterization during laparoscopic cholecystectomy is unwanted, but sometimes unavoidable complication/process. However its effect on postoperative pain is not studied with detail in literature.

Official Title
-----------------
Unintentional Liver Cauterization Increases the Postoperative Pain After Laparoscopic Cholecystectomy: A Prospective Controlled Blinded Trial

Conditions
-----------------
Laparoscopic Cholecystectomy, Postoperative Pain

Intervention / Treatment
-----------------
* Procedure: Laparoscopic cholecystectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status I-II Presumptive diagnosis of benign gallbladder disease Exclusion Criteria: The patients with concurrent chronic disease like osteoporosis, and liver, pulmonary or renal disease, malignant disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study<br>liver cauterized during laparoscopic cholecystectomy. | Procedure: Laparoscopic cholecystectomy<br> <br> |
| Control<br>liver not-cauterized during laparoscopic cholecystectomy. | Procedure: Laparoscopic cholecystectomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analog scale (VAS) abdominal pain scores |  | Postoperative 2nd hour | 
| Visual analog scale (VAS) abdominal pain scores |  | Postoperative 24th hour |
Transfusion-Transmitted Cytomegalovirus Prevention in Neonates

Study Overview
=================
Brief Summary
-----------------
To evaluate the capacity of intravenously administered cytomegalovirus (CMV)-immune globin (CMVIG) to immunize high risk premature infants against CMV infections.

Detailed Description
-----------------
BACKGROUND: Premature infants who require multiple blood transfusions have a 15-30 percent incidence of cytomegalovirus infections. Many of these infections result in severe disease, with a mortality of about 20 percent. In theory, the infection could be avoided by using blood and blood products exclusively from CMV antibody negative donors. The use of such blood is impractical because it would require the rejection of approximately 40 percent of all blood donors. Studies had suggested that passively acquired antibody could reduce the incidence of disease in exposed neonates. This provided the rationale for the use of passive immunization with hyperimmune globin in premature infants likely to require multiple transfusions. Lots of high titer CMV immune globulin suitable for intravenous administration were prepared using a technique of screening outdated blood bank plasma for units with high levels of antibody to CMV. DESIGN NARRATIVE: Randomized, double-blind. Subjects received either prophylactic CMVIG-intravenously or a placebo. Infants were followed for up to 12 weeks after discharge. Total sample size was expected to be 650. The study completion date listed in this record was inferred from last publication listed in the Citations section of this study record.

Conditions
-----------------
Blood Transfusion, Cytomegalovirus Infections

Intervention / Treatment
-----------------
* Drug: immunoglobulins


Participation Criteria
=================
Eligibility Criteria
-----------------
Neonates at high risk for transfusion-transmitted CMV infection. The neonates were either premature, of low birth weight, or had respiratory distress requiring the presence of an umbilical catheter.

Ages Eligible for Study
-----------------
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: immunoglobulins|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals

Study Overview
=================
Brief Summary
-----------------
The proposed study will examine the implementation of a Human Papillomavirus (HPV) self-sampling intervention for unscreened and under-screened transgender men and transmasculine individuals living in South Florida. The study will enroll participants to receive this cervical cancer screening intervention in community venues. The purpose of this study is to pilot the self-sampler for feasibility and acceptability within this underserved population.

Official Title
-----------------
HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals

Conditions
-----------------
Cervical Cancer Screening

Intervention / Treatment
-----------------
* Behavioral: HPV self-sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Self-identify as transgender male or as transmasculine Assigned female sex at birth English speaking ages 25-65 years report not having had a pap smear in the last three years if age 30 and over, report not having a Pap smear/HPV co-test in the past 5 years Exclusion Criteria: • Those who report having had a hysterectomy Those who report having history of cervical cancer Adults unable to consent Those who are pregnant Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HPV Self-sampling<br>All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon. | Behavioral: HPV self-sampling<br>* Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acceptability of HPV self-sampling Questionnaire | This questionnaire, designed with substantial input from community partners, will gauge how acceptable the participants find HPV self-sampling through both closed and open-ended questions regarding ease of use, preference of self-sampler vs. physician-collected Pap smear, as well as open-ended inquiries regarding the self-sampling process. | This questionnaire will be administered immediately after participants self-sample |
A Feasibility Study on Prediction of an ICD Shock by ICD-derived Data

Study Overview
=================
Brief Summary
-----------------
The primary hypothesis is that an ICD shock may be predicted days in advance by a combined score derived from different data obtainable from the ICD

Official Title
-----------------
PREDICTion of Implantable-Cardioverter Defibrillator Shock Study

Conditions
-----------------
Sudden Cardiac Arrest, Ventricular Tachycardia, Ventricular Fibrillation

Intervention / Treatment
-----------------
* Device: ICD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≧ 18 and ≦ 80 Patients have documented spontaneous and sustained ventricular arrhythmias in the last six months prior to the enrollment Patients who are in sinus rhythm, have dual-chamber ICD or CRT-D implanted at least one month before enrollment Patients who are in atrial fibrillation, have single-chamber ICD or CRT-D implanted at least one month before enrollment Patients who are compliant to CareLink follow-up Exclusion Criteria: Patients who are pregnant Patients who are incapable of giving consent to the study Patients who have a life-expectancy of less than 2 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ICD recipients<br>ICD recipients with documented cardiac arrest or ventricular arrhythmias | Device: ICD<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICD-derived T-wave alternans amplitude before ICD shock | The T-wave alternans amplitude before an ICD shock will be measured in mV and compared to the baseline T-wave alternans amplitude | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
implantable-cardioverter-defibrillator, ventricular tachycardia, ventricular fibrillation, sudden cardiac arrest